TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39348705
Drug: <7 g/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <7 g/dL transfusion strategy
Study: 39349061
Drug: Neoadjuvant ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy (IPI-NIVO-CRT); IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later; Thoracic radiotherapy was 50 or 60 Gy, in once-daily doses of 2 Gy.
Study: 39349282
Drug: Optimal secondary
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal secondary prevention therapy at discharge
Study: 39349554
Drug: E2 cypionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 cypionate (5 mg, IM) and micronized P4 (200 mg, PO)
Study: 39350021
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose intake during OGTT
Study: 39350097
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (access to the programme five months after randomization)
Study: 39350107
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in lateral incisor positions
Study: 39350107
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in canine positions
Study: 39350954
Drug: Adjunctive minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive minocycline
Study: 39350954
Drug: Adjunctive celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive celecoxib
Study: 39351312
Drug: Preoperative exercise
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative exercise intervention (4-week program including aerobic exercise three times a week, muscle strengthening exercise twice a week, and respiratory muscle exercise once a day)
Study: 39351353
Drug: Unsupervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised exercise (UNSUP) - 16-week, telehealth-based, periodized aerobic and resistance exercise program, performed three days per week, using the same exercise prescription parameters as the SUP group.
Study: 39351849
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated without the use of IV therapy
Study: 39351849
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not on antihypertensive therapy at enrollment
Study: 39352135
Drug: SPR720, phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR720, phosphate ester prodrug, oral administration, dosage and duration not specified
Study: 39352476
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g nori (aiming to provide 2.4 µg vitamin B)
Study: 39352693
Drug: TEACHH intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TEACHH intervention (health literacy-informed teaching, pictorial materials, color- and shape-coded medication labels, medication demonstration, two Zoom-based follow-up visits)
Study: 39352751
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV ascorbic acid therapy
Study: 39352775
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% via intercostal catheter at a flow rate of 6-8 ml/h for 72 hours after surgery
Study: 39353160
Drug: Serum Epstein-Barr
Normalized name: Epstein-Barr virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Epstein-Barr virus (EBV) viral capsid antigen/nuclear antigen 1-immunoglobulin A antibody tests in the screening group
Study: 39353163
Drug: Roxadustat (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (100, 120, or 150 mg three times a week for 12 weeks)
Study: 39353584
Drug: Clinical Frailty
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Frailty Scale administered at baseline, 3 months, and 12 months post-inclusion
Study: 39353584
Drug: EQ-5D-5L administered
Normalized name: Anthelcide EQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ-5D-5L administered at baseline, 3 months, and 12 months post-inclusion
Study: 39353631
Drug: SARS-CoV-2 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccination (first dose)
Study: 39353631
Drug: SARS-CoV-2 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccination (second dose)
Study: 39353677
Drug: DMEK plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMEK plus topical placebo
Study: 39353677
Drug: DSO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSO plus topical ripasudil 0.4%
Study: 39353749
Drug: Leronlimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (700 mg)
Study: 39354195
Drug: CD5-gene-edited CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5-gene-edited CAR-T cell therapy targeting CD5
Study: 39354558
Drug: Brazilian Cardioprotective
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts (10 g of peanuts; 10 g of cashew; 10 g of Brazil nuts)
Study: 39354558
Drug: Brazilian Cardioprotective
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts
Study: 39354619
Drug: Double-dose ESWT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose ESWT (4000 pulses per session)
Study: 39354619
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (half the dose, 2000 pulses per session)
Study: 39354625
Drug: JS007 (anti-CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS007 (anti-CTLA-4 antibody) administered intravenously every 3 weeks at doses of 0.03, 0.3, 1, 3, and 10 mg/kg.
Study: 39354625
Drug: JS007 (anti-CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS007 (anti-CTLA-4 antibody) administered intravenously.
Study: 39355793
Drug: Prolonged 120-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged 120-h meropenem antibiotic prophylaxis (Group B)
Study: 39355793
Drug: Standard 24-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 24-h antibiotic prophylaxis (Group A)
Study: 39355924
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonist treatment in patients with PA
Study: 39356043
Drug: Brivaracetam (BRV)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brivaracetam (BRV) treatment, median dose 1.0 mg/kg/day (range 0.4-7.5 mg/kg/day)
Study: 39356138
Drug: Panitumumab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4)
Study: 39356537
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) - loading dose of 10 mg/kg followed by maintenance infusion of 5 mg/kg per hour during surgery
Study: 39356943
Drug: Superior rectal
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior rectal artery embolization
Study: 39356946
Drug: Percutaneous Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous Ethanol Injection
Study: 39357673
Drug: Beans (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beans (120 g, ∼0.75 cups)
Study: 39357673
Drug: Peas (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peas (120 g, ∼0.75 cups)
Study: 39358355
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg davunetide/daily
Study: 39358355
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg davunetide/twice-daily
Study: 39358661
Drug: Selvigaltin (GB1211)
Normalized name: GB1211
DrugBank: GB1211 (DB17499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selvigaltin (GB1211) 100 mg oral
Study: 39358806
Drug: Exenatide (EQW)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EQW) 2 mg once weekly
Study: 39359014
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy for STEMI
Study: 39359872
Drug: Physical facial
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physical facial nerve rehabilitation (PFNR) therapy alone (neuromuscular retraining and Kabat proprioceptive neuromuscular facilitation)
Study: 39360368
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg/day orally
Study: 39361946
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy (SOC) - once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin
Study: 39362046
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox (ONTAK) at 5 μg/kg
Study: 39362046
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox (ONTAK) at 15 μg/kg
Study: 39362046
Drug: Denileukin diftitox
Normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Denileukin diftitox (ONTAK) at 25 μg/kg
Study: 39362248
Drug: Ziftomenib (50-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziftomenib (50-1000 mg) orally once daily in 28-day cycles (Phase 1a)
Study: 39362248
Drug: Ziftomenib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziftomenib (600 mg) in Phase 1b
Study: 39362248
Drug: Ziftomenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziftomenib (200 mg) in Phase 1b
Study: 39362249
Drug: Capmatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib (400 mg orally twice daily)
Study: 39362907
Drug: Manual lymphatic
Normalized name: PINPOINT Lymphatics Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymphatic drainage (MLD) administered from 180 to 195 minutes
Study: 39363095
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus testosterone
Study: 39363100
Drug: Doxycycline post-exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline post-exposure prophylaxis (200-mg dose taken after condomless sex)
Study: 39363320
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment based on resistance mechanism
Study: 39363801
Drug: Allergen Immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen Immunotherapy (AIT)
Study: 39363801
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AIT and biologics
Study: 39364940
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) therapy
Study: 39365957
Drug: FDG-PET-guided adaptive
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG-PET-guided adaptive treatment (mean 71 Gy in 30 fractions, mean lung dose 17.9 Gy)
Study: 39365957
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (60 Gy/30 fractions)
Study: 39365960
Drug: Glofitamab monotherapy
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab monotherapy with obinutuzumab pretreatment (Gpt) 1,000 or 2,000 mg 7 days before glofitamab; glofitamab step-up dosing on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles.
Study: 39365992
Drug: Ruxolitinib 10mg
Normalized name: RUXOLITINIB 10MG ORAL TAB
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 10mg twice daily for up to 12 cycles
Study: 39366653
Drug: Bilateral sphenopalatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sphenopalatine ganglion block (SPGB) with 5 mL lidocaine 2% on each side (G1)
Study: 39366653
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and bilateral saline injection of 5 mL on each side (G2)
Study: 39366722
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) initiated and increased to maximum tolerated dose by week 12
Study: 39366722
Drug: Continued MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued MTX dose with subcutaneous adalimumab
Study: 39366751
Drug: Niraparib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib monotherapy
Study: 39366752
Drug: HBM4003 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 weeks
Study: 39367366
Drug: ASSIP (Attempted
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASSIP (Attempted Suicide Short Intervention Program) plus treatment as usual
Study: 39367439
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention using videoconferencing technology for linking incarcerated women to community MOUD treatment.
Study: 39367749
Drug: Impulse oscillometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impulse oscillometry for evaluating SAD, defined as R5-R20 ⩾0.07 kPa/L/s.
Study: 39368130
Drug: Pediatric COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric COVID-19 vaccine uptake influenced by concerns and misinformation surrounding the new vaccine.
Study: 39368130
Drug: Pediatric COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric COVID-19 vaccine uptake influenced by witnessing others' vaccine and pandemic experiences.
Study: 39368130
Drug: Pediatric COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric COVID-19 vaccine uptake influenced by participation in social activities.
Study: 39368130
Drug: Pediatric COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric COVID-19 vaccine uptake influenced by the politicization of and political climate surrounding the vaccine.
Study: 39368130
Drug: Pediatric COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric COVID-19 vaccine uptake influenced by health education surrounding the vaccines.
Study: 39368870
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) app
Study: 39368871
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) self-help app
Study: 39369129
Drug: Time-to-therapy >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-to-therapy > 2 years
Study: 39369129
Drug: Time-to-therapy >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-to-therapy > 2 years in low-risk subgroup
Study: 39369239
Drug: Five-session telephone-delivered
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-session telephone-delivered behavioural activation treatment as an add-on to treatment as usual
Study: 39369239
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual in primary care
Study: 39369249
Drug: Inhalation induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation induction
Study: 39370144
Drug: Bictegravir/emtricitabine/tenofovir alafenamide
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for 48 weeks
Study: 39371161
Drug: Comparison to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison to previous solutions trained with ground truth acoustic voice recordings
Study: 39371165
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g daily of KE (bis-octanoyl (R)-1,3-butanediol)
Study: 39372262
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin D (cholecalciferol 50 mcg)
Study: 39372369
Drug: KETO diet
Normalized name: Keto-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: KETO diet (carbohydrate restriction-induced LDL-C ≥190 mg/dL)
Study: 39373173
Drug: FIT threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT threshold of 15 μg/g
Study: 39373173
Drug: FIT threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT threshold of 47 μg/g
Study: 39373173
Drug: FIT threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT threshold of 150 μg/g
Study: 39373311
Drug: BI 1820237
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1820237 (0.075-2.4 mg)
Study: 39373311
Drug: BI 1820237
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1820237 (1.2 mg)
Study: 39373311
Drug: BI 1820237
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1820237 (0.025-1.2 mg) + liraglutide (0.6 mg)
Study: 39373498
Drug: Post-natal antibiotic
Normalized name: B-Natal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-natal antibiotic exposure
Study: 39373498
Drug: Antibiotic-naive infants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-naive infants
Study: 39373498
Drug: Overall presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall presence of antibiotic resistance genes (ARGs)
Study: 39373498
Drug: Preterm infants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm infants without direct or intrapartum antibiotic exposure
Study: 39373831
Drug: Hello Bundle
Normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hello Bundle intervention (6 components: Hello campaign posters, email reminders, integrating greetings in morning huddles, hello jars, lead-by-example initiatives, daily updated hello board)
Study: 39373843
Drug: STS101 (5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: STS101 (5.2 mg dihydroergotamine nasal powder)
Study: 39373844
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER (extended-release capsules) at doses between 200 and 600 mg/day
Study: 39373844
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER (extended-release capsules) at doses ≥ 400 mg/day
Study: 39373844
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER (extended-release capsules)
Study: 39374004
Drug: Masked taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masked taper plus cognitive behavioral therapy-augmented program (MTcap)
Study: 39374004
Drug: Standard CBTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CBTI plus supervised (unmasked) gradual taper (SGT)
Study: 39374216
Drug: Neck-specific exercise
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck-specific exercise (NSE) supervised by a physiotherapist twice a week for 12 weeks
Study: 39374480
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted therapies (MTTs) post-MTB evaluation
Study: 39374480
Drug: Approved tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved tyrosine kinase inhibitors
Study: 39374480
Drug: Standard chemotherapy/immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy/immunotherapy
Study: 39374480
Drug: No matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: No matched targeted therapy (MTT)
Study: 39374521
Drug: Asciminib 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asciminib 80 mg daily plus dasatinib 140 mg daily plus prednisone 60 mg/m2 daily
Study: 39374532
Drug: Pitavastatin, 4
Normalized name: Pitavastatin, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin, 4 mg daily
Study: 39374555
Drug: Brief Mindfulness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Mindfulness Intervention (Brief MI) - 15-minute audio mindfulness practice daily from embryo transfer to pregnancy test (total 180-210 minutes)
Study: 39374555
Drug: Extremely Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extremely Brief Meditation (EBMI) - Weekly 40-minute sessions with a meditator instructor (total 80 minutes)
Study: 39374605
Drug: Booster group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster group (received homologous booster dose at month 18)
Study: 39374638
Drug: Early 3-month
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplatelet therapy (experimental arm)
Study: 39374638
Drug: Lifelong single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifelong single antiplatelet therapy (standard arm)
Study: 39374788
Drug: Composite intravenous
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite intravenous lipid emulsion (CO-ILE) with fish oil
Study: 39375168
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with avutometinib plus defactinib
Study: 39375168
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of treatment